ARG
CNS Tumors
ITM Solucin GmbHSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the CNS Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Entrectinib Hoffmann-La Roche | Phase 1/2 | CC |
Avutometinib Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
LYSINE ITM Solucin GmbH | Phase 1 | CC |
DOTATOC ITM Solucin GmbH | Phase 1 | CC |
Lorazepam Masonic Cancer Center, University of Minnesota | N/A | D |
URSODEOXYCHOLIC ACID Masonic Cancer Center, University of Minnesota | N/A | D |
Same molecule, other indications
ARG is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →